<DOC>
	<DOCNO>NCT02648269</DOCNO>
	<brief_summary>This Study first evaluate safety pharmacokinetics single intravenous dose SEL-110 , nanoparticle contain rapamycin , subject elevate blood uric acid level . This follow , separate subject , evaluation safety , pharmacokinetics , pharmacodynamics immunogenicity single intravenous dose SEL-212 , SEL-037 ( pegsiticase ) plus SEL-110 , subject elevate blood uric acid level . Uricase enzyme convert uric acid readily soluble allantoin excrete SEL-110 design prevent unwanted anti-drug-antibodies ( ADAs ) forming .</brief_summary>
	<brief_title>Safety Pharmacodynamics SEL-212 ( Pegsiticase + SEL-110 ) Subjects With Elevated Blood Uric Acid Levels</brief_title>
	<detailed_description>This Study first evaluate safety pharmacokinetics single intravenous dose SEL-110 , nanoparticle contain rapamycin , subject elevate blood uric acid level . This follow , separate subject , evaluation safety , pharmacokinetics , pharmacodynamics immunogenicity single intravenous dose SEL-212 , SEL-037 ( pegsiticase ) plus SEL-110 , subject elevate blood uric acid level . Uricase enzyme convert uric acid readily soluble allantoin excrete SEL-110 design prevent unwanted anti-drug-antibodies ( ADAs ) forming . Cohorts subject SEL-110 arm study give single , ascend intravenous dose SEL-110 monitor safety rapamycin level ( pharmacokinetics ) 30 day . Cohorts subject SEL-212 arm study give single , ascend intravenous dose SEL-110 fix dose SEL-037 monitor safety , rapamycin level , SEL-037 level , uric acid level anti-drug-antibodies ( ADAs ) SEL-037 30 day . One additional control group receive single intravenous infusion SEL-037 fix dose monitor safety , SEL-037 level , uric acid level anti-drug-antibodies ( ADAs ) SEL-037 30 day</detailed_description>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Male female subject age 21 70 inclusive . Female subject must nonchildbearing potential ; Has screen visit serum uric acid ≥ 6 mg/dL , without history gout ; The use allopurinol , febuxostat ( Uloric® ) , probenecid uric acidlowering therapy permissible dose stable least month prior screen visit ; Has adequate venous access able receive IV therapy ; Evidence personally sign date informed consent document indicate subject inform pertinent aspect study ; Prior exposure experimental market uricase ( arm receive SEL037 SEL212 ) ; History allergy pegylated product ; Glucose6phosphate dehydrogenase deficiency know catalase deficiency ; History hematological autoimmune disorder , immunosuppressed immunocompromised ; Presently take drug classify CYP3A4 inducer inhibitor ; Has participate clinical trial within 30 day Screening ;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>